Discontinued — last reported Q4 '25
Interest Income
Vertex Pharmaceuticals Interest Income decreased by 3.0% to $121.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.9%, from $128.20M to $121.90M. Over 4 years (FY 2021 to FY 2025), Interest Income shows an upward trend with a 216.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher interest income suggests a strong cash position or a favorable interest rate environment for the company's investments.
Detailed definition
Interest income is the revenue earned from cash deposits, marketable securities, and other interest-bearing investments....
Peer comparison
Varies based on cash management strategies; companies with large cash piles will report higher interest income than those with high debt.
interest_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.10M | $1.10M | $1.20M | $1.60M | $10.80M | $46.20M | $86.00M | $122.60M | $144.70M | $167.90M | $179.50M | $181.20M | $156.50M | $132.20M | $128.20M | $120.90M | $122.40M | $125.70M | $121.90M |
| QoQ Change | — | +0.0% | +9.1% | +33.3% | +575.0% | +327.8% | +86.1% | +42.6% | +18.0% | +16.0% | +6.9% | +0.9% | -13.6% | -15.5% | -3.0% | -5.7% | +1.2% | +2.7% | -3.0% |
| YoY Change | — | — | — | — | +881.8% | >999% | >999% | >999% | >999% | +263.4% | +108.7% | +47.8% | +8.2% | -21.3% | -28.6% | -33.3% | -21.8% | -4.9% | -4.9% |
Business Segments
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | $181.20M | $156.50M | $132.20M | $128.20M | $120.90M | $122.40M | $125.70M | $121.90M |
| Total | $181.20M | $156.50M | $132.20M | $128.20M | $120.90M | $122.40M | $125.70M | $121.90M |
Pharmaceuticals was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Interest Income at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's interest income?
- Vertex Pharmaceuticals (VRTX) reported interest income of $121.90M in Q4 2025.
- How has Vertex Pharmaceuticals's interest income changed year-over-year?
- Vertex Pharmaceuticals's interest income decreased by 4.9% year-over-year, from $128.20M to $121.90M.
- What is the long-term trend for Vertex Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's interest income has grown at a 216.4% compound annual growth rate (CAGR), from $4.90M to $490.90M.
- What does interest income mean?
- The money earned from interest on cash holdings and investments.